Stock FDMT 4D MOLECULAR THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases 4D Molecular Therapeutics, Inc.

Equities

FDMT

US35104E1001

Real-time Estimate Cboe BZX
Other stock markets
 13:41:24 2024-05-09 EDT 		5-day change 1st Jan Change
25.92 USD -1.54% Intraday chart for 4D Molecular Therapeutics, Inc. -2.92% +26.41%
04-15 Barclays Starts 4D Molecular Therapeutics With Overweight Rating, $45 Price Target MT
04-15 RBC Raises Price Target on 4D Molecular Therapeutics to $40 From $35, Keeps Outperform Rating, Speculative Risk Qualifier MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
4DMT to Participate in Upcoming Investor Conference
GL
4DMT to Participate in Upcoming Investor Conference
AQ
4DMT Announces Presentations at ARVO 2024 Annual Meeting
GL
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
GL
4DMT to Participate in Upcoming Investor Conferences
GL
4DMT Reports Full Year 2023 Financial Results and Operational Highlights
GL
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
GL
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
AQ
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
GL
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
GL
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
AQ
4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
AQ
4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
GL
4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
GL
4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
AQ
4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
GL
4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
AQ
4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates
AQ
4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates
GL
4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FDMT Stock
  4. News 4D Molecular Therapeutics, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW